News - Keryx Biopharmaceuticals, Mercury Pharma

Filter

Popular Filters

US nephrologists views on prescribing Roche’s Mircera

02-10-2013

Among surveyed US nephrologists, familiarity with Swiss drug major Roche's Mircera is low, but is still…

InjectaferKeryx BiopharmaceuticalsMirceraNeurologicalNorth AmericaPharmaceuticalRocheZerenex

Keryx Biopharma files for US approval of Zerenex

09-08-2013

Keryx Biopharmaceuticals (Nasdaq: KERX) says it has submitted a New Drug Application to the US Food and…

BiotechnologyKeryx BiopharmaceuticalsNephrology and HepatologyNorth AmericaRegulationZerenex

Amdipharm and Mercury Pharma merge

15-03-2013

As has been expected, Amdipharm and Mercury Pharma - both subsidiaries of Channel Islands-based private…

Amdipharm Mercury CompanyGenericsMercury PharmaMergers & Acquisitions

Keryx Biopharma rockets on new Zerenex data and plans to file for approval

29-01-2013

USA-based Keryx Biopharmaceuticals (Nasdaq: KERX) saw its shares close up a whopping 77% to $4.70 in…

BiotechnologyKeryx BiopharmaceuticalsNephrology and HepatologyPharmaceuticalRegulationRenagelRenvelaResearchSanofiZerenex

Cinven snaps up Amdipharm for £367 million

15-10-2012

Channel Islands-based private equity firm Cinven has reached agreement to acquire UK-based niche generic…

AmdipharmCinvenGenericsMercury PharmaMergers & Acquisitions

Cinven to acquire Mercury Pharma for $730 million

20-08-2012

Cinven, a Channel Islands-based private equity firm, said last Friday that it has reached agreement to…

CinvenGenericsMercury PharmaMergers & AcquisitionsPharmaceutical

News briefs: Roche's dalcetrapib; Coherus/Daiichi deal; Mercury Pharma; AEterna Zentaris

08-05-2012

Swiss drug major Roche (ROG: SIX) saw its shares drop 4.5% to 159.30 Swiss francs by around midday yesterday,…

AEterna ZentarisBiotechnologyCoherus BioSciencesDaiichi SankyodalcetrapibGenericsKeryx BiopharmaceuticalsLicensingMercury PharmaMergers & AcquisitionsperifosinePharmaceuticalResearchRoche

AEterna Zentaris and Keryx shares tank as cancer drug flops in Ph III

03-04-2012

Canadian drug developer AEterna Zentaris (TSX: AEZ) and US licensee Keryx Pharmaceutical (Nasdaq: KERX)…

AEterna ZentarisKeryx BiopharmaceuticalsLicensingNephrology and HepatologyOncologyperifosinePharmaceuticalResearchZerenex

Goldshield and affiliates rebrand as Mercury Pharma

22-03-2012

Goldshield, an international speciality pharmaceutical company selling niche generic prescription and…

GenericsGoldshieldMarkets & MarketingMercury Pharma

Back to top